Lupin Limited, a global pharmaceutical leader, has announced its plan to adopt Honeywell’s Solstice® Air (HFO-1234ze cGMP) as a next-generation propellant in the development of pressurized metered-dose inhalers (pMDIs). Aimed at treating asthma and chronic obstructive pulmonary disease (COPD), this move marks a significant step in reducing the environmental impact of respiratory treatments.
Solstice Air, a non-flammable, medical-grade propellant, presents a sustainable alternative to traditional hydrofluorocarbon (HFC)-based propellants used in inhalers. With the ability to cut greenhouse gas emissions by up to 99.9%, it offers a major advancement in the fight against climate change. Lupin is set to become the first pharmaceutical company in India to utilize Solstice Air at scale in its inhalers.
“This partnership with Honeywell is a milestone in our mission to combine high-quality patient care with environmental stewardship,” said Vinita Gupta, CEO of Lupin. “By integrating Solstice Air, we are enhancing treatment efficacy for asthma and COPD patients while drastically reducing our carbon footprint.”
Jeff Dormo, President at Honeywell’s Energy and Sustainability Solutions division, emphasized the environmental benefits of this collaboration: “Solstice Air enables Lupin’s inhalers to deliver safe and effective respiratory treatments with a significantly lower environmental impact. We are proud to support innovation that improves healthcare outcomes while addressing climate challenges.”
The collaboration is currently in the negotiation phase, pending execution of definitive agreements acceptable to both parties. This partnership reflects both companies' commitment to sustainability, innovation, and improved global health outcomes.